Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 184-191 , June 2009

Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery

  • Rishi Paliwal, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Shivani Rai, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Bhuvaneshwar Vaidya, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Kapil Khatri, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Amit K. Goyal, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Neeraj Mishra, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Abhinav Mehta, MPharm

      Affiliations

    • Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H.S. Gour Vishwavidyalaya, Sagar, India
    • ,
  • Suresh P. Vyas, PhD

      Affiliations

    • Nanomedicine Research Centre, ISF College of Pharmacy, Moga, Punjab, India
    • Corresponding Author InformationCorresponding author.

Received 12 August 2007 ,Accepted 24 August 2008.

References 

  1. Davidson N. Cellular and molecular mechanisms of small intestinal lipid transport. In:  Johnsons LR editors. Physiology of the gastrointestinal tract. 3rd ed. New York: Raven Press; 1994;p. 909
  2. Vyas SP. In: Lymphatics: drug targeting and transportation, In: Jain NK, editor. Controlled and novel drug delivery. New Delhi: CBS, India; 1997;p. 169–183
  3. Vyas SP, Jaitely V, Kanaujia P. Synthesis and characterization of palmitoyl propranolol hydrochloride auto-lymphotrophs for oral administration. Int J Pharm. 1999;186:177–189
  4. Griffin BT, O’Driscoll CM. Targeting of saquinavir to the intestinal lymphatics in the rat—the influence of P-glycoprotein and cytochrome P450 modulators. AAPS Pharm Sci. 2001;3:T3175
  5. Yoshikawa H, Muranishi S, Kato C, Sezaki H. Bifunctional delivery system for selective transfer of Bleomycin into lymphatics via enteral route. Int J Pharm. 1981;8:291–302
  6. Muranishi S, Fujita T, Murakami M, Yamamoto A. Potential for lymphatic targeting of peptides. J Control Release. 1997;46:157–164
  7. Hussain N, Jaini PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res. 1997;14:613–618
  8. Clark MA, Japson MA, Hirst BH. Exploiting M cells for drug and vaccine drug delivery. Adv Drug Deliv Rev. 2001;50:81–106
  9. Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatics transport of Halofantrine and assessment of mass balance in lymph–cannulated and non-cannulated rats. J Pharm Sci. 2000;89:1073–1084
  10. Khoo SM, Edwards GA, Porter CJ, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90:1599–1607
  11. Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61–80
  12. Humberstone AJ, Charman WN. Lipid-based vehicle for oral delivery of poorly water-soluble drug. Adv Drug Deliv Rev. 1997;25:103–128
  13. O'Driscoll CM, Myers RA, Stella VJ. Blood and lymph transport of DDT after oral and parenteral administration to anaesthetized rats. Int J Pharm. 1991;73:177–183
  14. Porter CJ, Charman SA, Charman WN. Lymphatic transport of Halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci. 1996;85:351–356
  15. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm. 2002;241:341–344
  16. Supersaxo A, Hein WR, Steffen H. Mixed micelles as a proliposomal, lymphotropic drug carrier. Pharm Res. 1991;8:1286–1291
  17. Mishina EV, Straubinger RM, Pyszczynski NA, Jusko WJ. Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. Pharm Res. 1993;10:1402–1410
  18. Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177
  19. Westesen K, Knoll Aktiengesellschaft , Ludwigshafen DE. Particles with modified physico-chemical properties, their preparation and uses.. United States patent US 6197349; March 6, 2001;
  20. Rai S, Paliwal R, Gupta PN, Khatri K, Goyal AK, Vaidya B, et al. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery sciences: one step up in nanotechnology. Curr Nano Sci. 2008;4:30–44
  21. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharm Res. 2000;42:337–343
  22. Hu FQ, Hong Y, Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm. 2004;273:29–35
  23. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751–757
  24. Zara GP, Cavalli R, Fundaro A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci. 2002;91:1324–1333
  25. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res. 1998;5:745–750
  26. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm. 2003;257:153–160
  27. Venkateshwarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627–638
  28. Moghbel A, Zand-Moghaddam A, Rezaee S, Pedram M. High-performance liquid chromatography determination of methotrexate in plasma. Iranian J Pharm Res. 2003;2:149–152
  29. Warshaw AL. A simplified method of cannulating the intestinal lymphatic of the rat. Gut. 1972;13:66–67
  30. Porter CJ, Charman WN. Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res. 2001;23:215–257
  31. Jacobs C, Kayser O, et al. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000;196:161–164
  32. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751–757
  33. Plain KJ, Wilson CG. The effect of different oils on the absorption of probucol in the rat. J PharMPharmacol. 1984;36:641–643

 Financial support by the University Grants Commission (UGC), New Delhi, INDIA, as JRF to one of the authors (Rishi Paliwal) is duly acknowledged.

PII: S1549-9634(08)00146-9

doi: 10.1016/j.nano.2008.08.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 2 , Pages 184-191 , June 2009

Article Tools

* Image Usage & Resolution